MUMBAI (Reuters) - Cipla Ltd, India's fifth-largest drugmaker by sales, reported a fall of 69 percent in its quarterly earnings on Tuesday, far short of analysts' forecasts.
Net profit for the January-March quarter was 808.7 million rupees ($12 million), compared with 2.60 billion rupees a year earlier. The average of forecasts by analysts polled by Thomson Reuters was for a profit of 3.79 billion rupees.
A company statement did not provide a reason for the profit fall, but said domestic sales for the quarter had risen about 16 percent in the quarter and contributed 40 percent to overall sales in fiscal 2016.
($1 = 67.7027 Indian rupees)
(Reporting by Zeba Siddiqui in Mumbai; Editing by Alexander Smith)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app